Advancing treatments for Neurological Disorders
With the innovative use of Alpha 1 Anti-trypsin, Ageronix stands at the forefront of Neurodegenerative Disease research.
A promising breakthrough in the development of new treatments for Neurological Disorders
Read our latest press release here
- FDA-Recognized
- Experienced Research Team
- Commitment to CMT Patients
- Pioneering AAT Therapies
- Leading the search for a cure
Three generations of AAT-therapy:
In recognition of our commitment, Ageronix was granted the Orphan Drug Designation (ODD) and the Rare Pediatric Disease (RPD) Designation by the FDA
-
PRE-CLINICAL DEVELOPMENT
- 2023 - FDA
AWARDS ODD
July, 2023 - FDA
AWARDS RPD
AUGUST, 2023 -
CLINICAL TRIALS
2024 -
For more information please
get in touch at:
info@ageronix.com or
+41 223 79 46 43
64, Avenue de la Roseraie 1205, Geneva - Switzerland